The ViALIA Trial - IDH1 Inhibitors and Aesus Ven

The original result showed an improvement in the overall survival of all patients who are over age 75. The median follow-up time is about three and a half years. And those on the top who have IDH1 or IDH2 mutations do particularly well with aesus ven, they benefit quite a bit more than they would if they had been randomized to placebo. Now going back to that Agile study I mentioned before that was published by Montecino Sin Blood showing IVO's were better than Venetoclax for non-IDH dependent triplets.